Anti-tumor immune response in ovarian cancer: clinical implications, prognostic significance and potential for novel treatment strategies
Ovarian cancer is one of the leading causes of cancer-related death among women. Disease relapse occurs in a high number of cases and treatment currently involves the use of chemotherapy with the use of paclitaxel and platinum-based agents. Resistance to the disease occurs in more than 70% of the ca...
Saved in:
Main Authors: | Nikos G. Gavalas (Author), Meletios A. Dimopoulos (Author), Aristotelis Bamias (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2011-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience
by: Maria Kaparelou, et al.
Published: (2022) -
Prognostic significance of tumor laterality in advanced ovarian cancer
by: Yuki Yamada, et al.
Published: (2021) -
Exercise-Induced Changes in Tumor Growth via Tumor Immunity
by: Polyxeni Spiliopoulou, et al.
Published: (2021) -
Significance of Immunogenic Cell Death-Related Prognostic Gene Signature in Cervical Cancer Prognosis and Anti-Tumor Immunity
by: Jiang S, et al.
Published: (2023) -
SPARC is a Novel Prognostic Biomarker for Ovarian Cancer and Associated with Immune Signatures and Drug Response
by: Xiaorong Guo, et al.
Published: (2024)